Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Wiselka

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Sexually Transmitted Infections|April 9, 1999
Fever, weight loss, and night sweats: infection or malignancy?A J Winter, M J Wiselka, J T Wilde, et al.
The Journal of Infection|May 1, 1988
Mycoplasma pneumoniae infection associated with Henoch-Schonlein purpuraS E Steare, M J Wiselka, J J Kurinczuk, et al.
The Journal of Infection|October 19, 2005
Disseminated Sporothix schenckii in a patient with AIDSS Hardman, I Stephenson, D R Jenkins, et al.
Lancet (London, England)|January 1, 2000
Parenteral ivermectin in Strongyloides hyperinfectionP L Chiodini, A J Reid, M J Wiselka, et al.
Postgraduate Medical Journal|January 2, 2003
New World leishmaniasis from SpainN Tomson, R P Symonds, A A Moir, et al.
Journal of Clinical Microbiology|April 1, 1992
Genetic similarity and maintenance of Candida albicans strains from a group of AIDS patients, demonstrated by DNA fingerprintingJ Schmid, F C Odds, M J Wiselka, et al.
Thorax|October 1, 1991
Prophylactic intranasal alpha 2 interferon and viral exacerbations of chronic respiratory diseaseM J Wiselka, K G Nicholson, J Kent, et al.
Sexually Transmitted Infections|April 4, 2006
Progressive symptoms and signs following institution of highly active antiretroviral therapy and subsequent antituberculosis therapy: immune reconstitution syndrome or infection?R F Miller, M Shahmanesh, M D Talbot, et al.
HIV Medicine|February 26, 2015
Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialS Sharma, A G Babiker, S Emery, et al.
Journal of Viral Hepatitis|January 21, 2014
The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapyM Backx, A Lewszuk, J R White, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Sexually Transmitted Infections|April 9, 1999
Fever, weight loss, and night sweats: infection or malignancy?A J Winter, M J Wiselka, J T Wilde, et al.
The Journal of Infection|May 1, 1988
Mycoplasma pneumoniae infection associated with Henoch-Schonlein purpuraS E Steare, M J Wiselka, J J Kurinczuk, et al.
The Journal of Infection|October 19, 2005
Disseminated Sporothix schenckii in a patient with AIDSS Hardman, I Stephenson, D R Jenkins, et al.
Lancet (London, England)|January 1, 2000
Parenteral ivermectin in Strongyloides hyperinfectionP L Chiodini, A J Reid, M J Wiselka, et al.
Postgraduate Medical Journal|January 2, 2003
New World leishmaniasis from SpainN Tomson, R P Symonds, A A Moir, et al.
Journal of Clinical Microbiology|April 1, 1992
Genetic similarity and maintenance of Candida albicans strains from a group of AIDS patients, demonstrated by DNA fingerprintingJ Schmid, F C Odds, M J Wiselka, et al.
Thorax|October 1, 1991
Prophylactic intranasal alpha 2 interferon and viral exacerbations of chronic respiratory diseaseM J Wiselka, K G Nicholson, J Kent, et al.
Sexually Transmitted Infections|April 4, 2006
Progressive symptoms and signs following institution of highly active antiretroviral therapy and subsequent antituberculosis therapy: immune reconstitution syndrome or infection?R F Miller, M Shahmanesh, M D Talbot, et al.
HIV Medicine|February 26, 2015
Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialS Sharma, A G Babiker, S Emery, et al.
Journal of Viral Hepatitis|January 21, 2014
The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapyM Backx, A Lewszuk, J R White, et al.
Pageof 5